Vical Inc., of San Diego, said preclinical evaluations of its Vaxfectin adjuvant in combination with cell culture-derived seasonal and pandemic influenza vaccines from Baxter International Inc., of Deerfield, Ill., were published online in Human Vaccines & Immunotherapeutics

Afraxis Inc., of San Diego, named Carmine Stengone president and CEO, and Christopher Rex chief scientific officer

Metreleptin was part of the alliance between BMS and AstraZeneca plc, of London, to buy out Amylin Pharmaceuticals Inc., of San Diego, which had metreleptin among its assets. (See BioWorld Today, July 5, 2012...La Jolla Pharmaceutical Co., of San Diego, treated the last patient in the Phase I (Part A) portion of the Phase I/II trial of GCS-100 in patients with chronic kidney disease (CKD

Details Date Anthera Pharmaceuticals Inc. (Hayward, Calif.) Common stock purchase agreement N/A $2 Anthera entered an $18.5M common stock purchase agreement with Lincoln Park Capital Fund LLC, under which it made an initial purchase of $2M in common stock priced at 64.8 cents apiece 4/9/13 Cardium Therapeutics Inc. (San Diego) Private placement of zero coupon Series A convertible preferred stock 0.004S $4 Cardium entered a definitive agreement with a single institutional health care fund

I think it is based on the relationship we've built with BMS, but this is a different franchise area, a different portion of our technology platform," said Simon Allen, chief business officer of San Diego-based Ambrx

Sunrise Securities Corp. $25 Ambit Biosciences Inc. (San Diego; AMBI)2 2/20/13 4.645S $13-$15 12.9 Citigroup Leerink Swann (co-lead) BMO Capital Markets Baird $65.03 Audeo Oncology Inc. (San Francisco; AURX)3 7/6/12 3.25S $14-$16 10.8 Leerink Swann Oppenheimer & Co. (co-lead) $49 Epizyme Inc. (Cambridge, Mass.; EPZM) 4/26/13 N/A N/A N/A Citigroup Cowen and Co. (co-lead) Leerink Swann (co-lead) JMP Securities Wedbush PacGrow Life Sci. $69 GlobeImmune Inc. (Louisville, Colo.; GBIM) 7/2/12

A report from real estate firm Jones Lang LaSalle in March lists San Diego as the number two biotechnology cluster in the U.S. Like any list, the ranking is debatable, especially by people in the San Francisco Bay Area who came in third...Looking forward, Panetta hopes that other high-tech industries in San Diego – telecommunication and software, for instance – can join the life sciences, combining the strengths of the region

were down nearly 10 percent Friday following Thursday's after-market release of first-quarter earnings, which included news that the San Diego-based biotech is pulling its European marketing application for obesity drug Belviq (lorcaserin), though the bigger disappointment may be the ongoing delay in Belviq's U.S

Total: $85.5M Year to Date: $204.55M Company (Location) Partner (Location) Amt. (M) Details Date Arena Pharmaceuticals Inc. (San Diego) Eisai Inc. (Woodcliff Lake, N.J.) $0.5 For the submission of a marketing authorization application for Belviq in Mexico for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults 4/2/13 Furiex Pharmaceuticals Inc. (Morrisville, N.C.) Menarini Group (Florence, Italy) $5 For the launch of Priligy in

Cardium Therapeutics Inc., of San Diego, said the April 2013 issue of Molecular Therapy published a paper, titled "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors

San Diego-based Abide's platform involves proteomic technology from the Scripps Research Institute

Ambit Biosciences Inc., of San Diego, set terms for its proposed initial public offering (IPO), aiming to raise $65 million by offering 4.6 million shares priced between $13 and $15

and Canada in partnership with the Leukemia and Lymphoma Society, which has previously supported the development of CPX-351 . (See BioWorld Today, Dec. 27, 2012.) The transaction, led by New York and San Diego-based life sciences venture capital firm Valence Life Sciences LLC, sold a total of 10,430,034 shares of common stock at $3

In the April 26, 2013, issue of Science, Dulcis and his colleagues at the University of California at San Diego have shown that sensory activation, in the form of changes to the light-dark cycle, can induce such transmitter switching, and that "the changes in transmitter affect behavior in an adult animal

In the April 26, 2013, issue of Science, Dulcis and his colleagues at the University of California at San Diego have shown that sensory activation, in the form of changes to the light-dark cycle, can induce such transmitter switching, and that "the changes in transmitter affect behavior in an adult animal

Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs...Pfenex Inc., of San Diego, awarded Glide Pharma, of Oxford, UK, a subcontract to develop a solid formulation containing the recombinant protective antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology, suitable for delivery with the Glide SDI (solid dose

Trius Therapeutics Inc., of San Diego, announced a range of clinical data for the experimental antibiotic tedizolid phosphate (TR-701) and a presentation on linezolid-resistant strain of bacteria

Receptos Inc., of San Diego, set a price range for its proposed initial public offering, anticipating selling 4.7 million shares priced between $14 and $16

Ligand Pharmaceuticals Inc., of San Diego, reported preclinical data showing highly targeted liver delivery of a clinically active NS5B polymerase inhibitor using the firm's HepDirect technology platform and also demonstrating that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in hepatitis C treatment...Optimer Pharmaceuticals Inc., of San Diego, said Australian regulators approved Dificid (fidaxomicin) tablets